Clinical Trial Update: Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating capmatinib for CNS efficacy in non-small cell lung cancer with brain metastases and cfDNA-positive MET alterations has been withdrawn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Capmatinib (capmatinib)

Snippet

Sponsor: Timothy Burns, MD, PHD | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: WITHDRAWN